Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

Slides:

Advertisements

Similar presentations

Dose-escalation patient response.

Advertisements

Figure 2 Response after initial increase in total tumour burden

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib by Kathryn.

Recent Advances in Targeting ROS1 in Lung Cancer

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets Case Rep Oncol 2016;9:

A, baseline and 4-week PET scan from patient 2 (MET c

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Xe-CT CBF maps in a patient with Moyamoya disease.

Precontrast coronal T1-weighted view shows metastatic nodules (long arrows) from breast cancer in the vicinity of the left BPL and another metastatic mass.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Otolaryngology referred this patient for imaging after palpating a mass in the “left parotid tail.” Axial contrast-enhanced CT scan through the mass reveals.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Case 2: 14-year-old boy with headache, vomiting, dizziness, and ringing in the ear. Case 2: 14-year-old boy with headache, vomiting, dizziness, and ringing.

Representative CT and PET/CT images of three patients with NSCLCs

Recent Advances in Targeting ROS1 in Lung Cancer

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Identification and characterization of a novel KRAS rearrangement in metastatic prostate cancer. Identification and characterization of a novel KRAS rearrangement.

Identification of the CD74–NRG1 fusion gene.

Fig F-FGln shows uptake in human gliomas undergoing progression.

Tumor sites and treatment timelines.

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.

Fig. 4 Click Chips combined with RT-ddPCR analysis can be used to monitor dynamic changes in CTC count and CTC-derived ALK/ROS1 rearrangements in patients.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

KD involving the postauricular area and occipital scalp in an 11-year-old boy. KD involving the postauricular area and occipital scalp in an 11-year-old.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

An 89-year-old man with supraglottic laryngeal cancer.

Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.

Representative CT and PET/CT images of three patients with NSCLCs

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.

Gene copy number analysis by multiplexed quantitative differential PCR for BRCA1 and BRCA2 for 23 DNA specimens obtained from patients of Hispanic ancestry.

Sagittal reconstruction of a CT scan of a 6-year-old boy (patient 3) after a fall (GCS = 15) demonstrates an REH (thick white arrow), which causes mild.

Duration of treatment and intervals of radiographic and ctDNA response

Influenza vaccine enhances NK cell function through IFN-α.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Change in FES uptake in the tumor during fulvestrant treatment.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Possible outcomes of therapeutic treatments using the spiral model.

Representative patient responses to ulixertinib.

Patient 10. Patient 10. A 67-year-old man after radiation therapy at an outside hospital for base-of-tongue cancer. A and B, Axial contrast-enhanced CT.

Molecular definitions of lung adenocarcinoma subtypes.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

siRNA screen validation.

Serial CT scan images from patient with a partial response.

BRAF in-frame deletion confers response to MAPK inhibition.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

A variety of ROS1 gene fusions occur across multiple tumor types.

Curative effect of W+T treatment in vivo.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Waterfall plots in 82 ipilimumab-refractory patients receiving nivolumab (3 mg/kg) with (n = 14) or without (n = 82) a peptide vaccine. Waterfall plots.

Presentation transcript:

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. A, schematic representation of the TFG–ROS1 fusion. ROS1 is located on chromosome 6q22 and TFG is located on 3q12. The breakpoint occurs in-frame between exon 4 of TFG and exon 36 of ROS1. B, CT scans before the initiation of crizotinib (left) and after 3 cycles of crizotinib (right) showing dramatic reduction in the tumor mass within the left lung. C, changes in Hgb, MCV, and ESR over the course of the patient's treatments. Arrows below the graphs, initiation of the indicated therapies. The high (H) and low (L) limits of normal for each measured parameter are indicated on the blue graphs. Christine M. Lovly et al. Cancer Discovery 2014;4:889-895 ©2014 by American Association for Cancer Research